Du är här

2018-07-24

AstraZeneca: Atacand to be divested to Cheplapharm in Europe

Agreement expands the commercial potential of Atacand in 28 European
countries

AstraZeneca has agreed to sell the commercial rights to Atacand
(candesartan cilexetil) and Atacand Plus (fixed-dose combination of
candesartan cilexetil and hydrochlorothiazide) in Europe to
Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a
prescription medicine for the treatment of heart failure and
hypertension.

Mark Mallon, Executive Vice President, Global Product & Portfolio
Strategy at AstraZeneca, said: "This agreement forms part of our
strategy of streamlining our portfolio of mature medicines to enable
reinvestment in our main therapy areas and bringing new medicines to
patients. Cheplapharm's strong European presence will help expand the
commercial potential of Atacand."

The agreement is expected to complete in the third quarter of 2018.
AstraZeneca will continue to manufacture and supply Atacand and
Atacand Plus under a supply agreement and will continue to
commercialise the medicines in all markets where it still holds the
rights.

Financial considerations

Cheplapharm will pay AstraZeneca $200 million on completion of the
agreement, plus a time-bound payment of $10 million and
sales-contingent milestones. The upfront and time-bound payments are
expected to be reported in the Company's financial statements in
2018. All income is expected to be reported as Other Operating
Income. In 2017, global Product Sales for Atacand and Atacand Plus
were $300 million, including $86 million in Europe. The agreement
does not impact the Company's financial guidance for FY 2018.

About Atacand

Atacand (candesartan cilexetil) is a selective, AT1 subtype
angiotensin II receptor antagonist blocker (ARB) that is indicated
for the treatment of hypertension and heart failure. Atacand is also
available in Europe as a fixed-dose combination of candesartan
cilexetil and hydrochlorothiazide (Atacand Plus). Atacand is
indicated for the management of hypertension in adults and
children/adolescents, as well as heart failure in adults. Atacand
Plus is indicated for the management of hypertension when monotherapy
is not sufficiently effective. Atacand was developed in collaboration
with Takeda. Each company holds the exclusive rights to the product
in certain markets. In other markets, Atacand is co-marketed by both
parties.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal & Metabolism
and Respiratory. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us
on Twitter @AstraZeneca.

Media Relations
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Gonzalo Viña UK/Global +44 203 749 5916
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677

Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Josie Afolabi +44 203 749 5631
Craig Marks Finance; Fixed Income; M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology; Other +1 240 477 3771
Christer Gruvris Brilinta; Diabetes +44 203 749 5711
Nick Stone Respiratory; Renal +44 203 749 5716
Jennifer Kretzmann Retail Investors +44 203 749 5824

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/atacand-to-be-divested-to-chepla...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.